Fundz
Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →

Hopstem secures its first Series C financing to advance hNPC01 for neurological conditions. New investors include Tasly Capital, Haibang Investment, and Guangzhou Health Industry Investment.

PRIVATEAug 10, 2026•about 2 hours ago

Round Type

Series C

HoustonBiotechnologyHealth CareTherapeutics

Investors

Longmen CapitalGuangzhou Health Industry InvestmentHaibang InvestmentTasly Capital

Description

Hopstem Biotechnology Inc. announced the first closing of its Series C financing aimed at accelerating clinical development for hNPC01. The financing includes participation from new and existing investors. Hopstem plans to use the funds to accelerate clinical programs for its therapy

Company Information

Company

Hopstem Biotechnology

Location

Houston, Texas, United States

About

Hopstem Biotechnology Inc. is a Houston-based biotechnology company focused on developing induced pluripotent stem cell-derived neural cell therapies. Their lead candidate, hNPC01, targets neurological conditions involving chronic motor dysfunction and has received several regulatory designations from the U.S. FDA. The company aims to accelerate clinical programs and commercial manufacturing of its therapies. Hopstem's strategy is built around addressing serious diseases with substantial unmet medical needs.

Predictive Intelligence
Strategic

ML-powered predictions for Hopstem Biotechnology's next move

Learn about Strategic plan

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.